MAP Pharmaceuticals MAPP
-
MAP Pharmaceutical: Timeline Of The NDA Resubmission
By Joe Gantoss : Shareholders are waiting for MAP's ( MAPP ) management updates and are desperate for every piece of information. This is to be expected as investors wonder about the future …
-
MAP Pharma: Still Potentially A Good Short Sell
… to fully understand the risks that are involved with short selling. Many investors were awaiting an approval for MAP Pharma ( MAPP ) migraine treatment, LEVADEX, on March 26th. Unfortunately, the company received a Complete Response Letter ( CRL ) and …
-
Keryx: Next Shot Is Zerenex
By ValueMax : Keyrx ( KERX) recently suffered a major setback after the news of the Phase III clinical trial of its anti-cancer drug KRX-0401(perifosine) failed to have any real effect in terms of significantly lengthening the life expectancy of those with colorectal cancer. Approximately 468 ...
-
Map Pharmaceuticals : The Levadex Levitation
By David Sobek : Map Pharmaceuticals ( MAPP ) recently received a complete response letter (CRL) from the FDA for its lead (and only) product, Levadex. Map Pharmaceuticals and its partner Allergan had a plan to co-promote Levadex …
-
New Morningstar Analyst Report - Pepco Holdings
… project, Mid-Atlantic Power Pathway, or MAPP . Pepco's transformation began in December ..... for Pepco Holdings is the $1.2 billion MAPP transmission project, which has been delayed ..... moderate setback for the company because MAPP represented nearly 40% of projected rate …
-
MAP Pharmaceuticals : Short Opportunity After The FDA CRL
By Joe Gantoss : On March 26th, 2012 MAP Pharmaceuticals , Inc. ( MAPP ) announced that the United States Food and Drug Administration [FDA] had issued a Complete Response Letter [CRL] to its New …
-
MAP Pharmaceuticals : Investment Consequences Stemming From Levadex Complete Response Letter
By Smith On Stocks : Summary I think that it is a question of when and not if Levadex is approved. The complete response letter or CRL issued for Levadex appears to be resolvable fairly quickly and could result in approval in July to October of 2012 in my best case scenario. In the worst case, I ...
-
MAP Pharma shares dive after FDA rejects migraine treatment
(Reuters) - Shares of MAP Pharmaceuticals Inc fell by a third in premarket trade on Tuesday, after health regulators rejected its orally inhaled treatment for migraine, but analysts remain...
-
Premarket gainers: [[OPXT]] +55%. [[WNC]] +9%. [[ISTA]] +8%. [[DANG]] +5%. [[RBS]] +3%. [[ARNA]] +3%. [[LEN]] +3%.Losers: [[ MAPP ]] -17%. [[MMR]] -16%. [[APOL]] -6%. [[NBG]] -6%. [[TOT]] -6%. [[OCLR]] ...
Premarket gainers: OPXT +55% . WNC +9% . ISTA +8% . DANG +5% . RBS +3% . ARNA +3% . LEN +3% . Losers: MAPP -17% . MMR -16% . APOL -6% . NBG -6% . TOT -6% . OCLR -3% . EXPE -3% . HEK -3% . EXXI -3% . Post your comment!
-
JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals ( MAPP ), by taking the long view that Levadex is an "attractive, approvable product" despite missing out on first-pass FDA ...
JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals ( MAPP ), by taking the long view that Levadex is an "attractive, approvable product" despite missing out on first-pass FDA approval …